Macrophage CD74 contributes to MIF-induced pulmonary inflammation by Takahashi, Koichiro et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
Respiratory Research
Open Access Research
Macrophage CD74 contributes to MIF-induced pulmonary 
inflammation
Koichiro Takahashi*1, Kiyokazu Koga1, Helena M Linge1, Yinzhong Zhang1, 
Xinchun Lin1, Christine N Metz2, Yousef Al-Abed3, Kaie Ojamaa1,4 and 
Edmund J Miller1,5
Address: 1Center for Heart and Lung Research, The Feinstein Institute for Medical Research, Manhasset, New York, USA, 2Medicinal Biochemistry, 
The Feinstein Institute for Medical Research, Manhasset, New York, USA, 3Medicinal Chemistry, The Feinstein Institute for Medical Research, 
Manhasset, New York, USA, 4Molecular Cardiovascular Research, The Feinstein Institute for Medical Research, Manhasset, New York, USA and 
5Departments of Medicine and Surgery, Albert Einstein College of Medicine, Bronx, New York, USA
Email: Koichiro Takahashi* - ktakahas.nshs@gmail.com; Kiyokazu Koga - kkoga@nshs.edu; Helena M Linge - hlinge@nshs.edu; 
Yinzhong Zhang - zyinzhong@nshs.edu; Xinchun Lin - XLin@med.miami.edu; Christine N Metz - cmetz@nshs.edu; Yousef Al-
Abed - yalabed@nshs.edu; Kaie Ojamaa - kojamaa@nshs.edu; Edmund J Miller - emiller@nshs.edu
* Corresponding author    
Abstract
Background: MIF is a critical mediator of the host defense, and is involved in both acute and
chronic responses in the lung. Neutralization of MIF reduces neutrophil accumulation into the lung
in animal models. We hypothesized that MIF, in the alveolar space, promotes neutrophil
accumulation via activation of the CD74 receptor on macrophages.
Methods: To determine whether macrophage CD74 surface expression contributes MIF-induced
neutrophil accumulation, we instilled recombinant MIF (r-MIF) into the trachea of mice in the
presence or absence of anti-CD74 antibody or the MIF specific inhibitor, ISO-1. Using macrophage
culture, we examined the downstream pathways of MIF-induced activation that lead to neutrophil
accumulation.
Results: Intratracheal instillation of r-MIF increased the number of neutrophils as well as the
concentration of macrophage inflammatory protein 2 (MIP-2) and keratinocyte-derived chemokine
(KC) in BAL fluids. CD74 was found to be expressed on the surface of alveolar macrophages, and
MIF-induced MIP-2 accumulation was dependent on p44/p42 MAPK in macrophages. Anti-CD74
antibody inhibited MIF-induced p44/p42 MAPK phosphorylation and MIP-2 release by
macrophages. Furthermore, we show that anti-CD74 antibody inhibits MIF-induced alveolar
accumulation of MIP-2 (control IgG vs. CD74 Ab; 477.1 ± 136.7 vs. 242.2 ± 102.2 pg/ml, p < 0.05),
KC (1796.2 ± 436.1 vs. 1138.2 ± 310.2 pg/ml, p < 0.05) and neutrophils (total number of
neutrophils, 3.33 ± 0.93 × 104 vs. 1.90 ± 0.61 × 104, p < 0.05) in our mouse model.
Conclusion: MIF-induced neutrophil accumulation in the alveolar space results from interaction
with CD74 expressed on the surface of alveolar macrophage cells. This interaction induces p44/
p42 MAPK activation and chemokine release. The data suggest that MIF and its receptor, CD74,
may be useful targets to reduce neutrophilic lung inflammation, and acute lung injury.
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Background
Macrophage migration inhibitory factor (MIF) is an
inflammatory mediator of innate and adaptive immune
responses. MIF protein is present in most cells including
pituitary cells, T cells, macrophages/monocytes, and is
released in response to infection and stress [1]. Plasma
MIF concentrations are elevated in patients with inflam-
matory diseases such as sepsis [2], ARDS [3,4] or rheuma-
toid arthritis [5]. In addition, plasma concentration of
MIF is positively correlated with the severity of sepsis
[6,7]. Furthermore, mice deficient in the MIF gene, or
those in which the MIF protein has been neutralized, are
protected from lethal endotoxemia and septic shock [8,9].
In lung inflammation and injury models, MIP-2 and KC
play key roles in neutrophil accumulation into the lungs
[10]. Neutrophils are an important component of the
inflammatory response in acute lung injury [11,12]. The
elimination of neutrophils can markedly decrease the
severity of lung injury in animal lung inflammation mod-
els [13]. MIF levels are increased in BAL fluid in lipopoly-
saccharide (LPS)-induced lung injury model [14], and
MIF neutralizing antibody blocks LPS-induced pulmo-
nary neutrophil accumulation in animal models [15,16],
suggesting that MIF can influence neutrophil accumula-
tion into the lungs.
CD74 (also known as a MHC class II invariant chain) is a
type II transmembrane protein, reported to be part of the
MIF receptor complex [17]. Several studies have shown
that CD74 is expressed both intracellularly and on the cell
surface in B cell lymphoma [18], T cell lymphoma,
melanoma cells [19] and gastric epithelial cells [20]. MIF
binds to cell surface CD74, and induces p44/p42 MAPK
phosphorylation and cell proliferation. Moreover neutral-
ization of CD74 inhibits MIF-induced cell proliferation in
B cells and fibroblasts [17]. Other recent studies have
shown that anti-CD74 antibody blocks MIF-CD74 bind-
ing on the cell surface of gastric epithelial cells [21], and
anti-CD74 antibody attenuated proliferation of prostate
cancer cells [22]. CD74 has a short N-terminal cytoplas-
mic domain of 28 amino acids and appears to lack intrac-
ellular signaling domains. Recently, CD44 has been
identified as an accessory protein required for MIF-CD74
signal transduction [23].
MIF is found at increased levels in BAL fluids from both
LPS induced lung inflammation [14] and polymicrobial
sepsis models [24]. BAL fluid-MIF levels in ARDS patients
were also significantly increased compared with healthy
controls [3]. However, little is known about the mecha-
nisms involved in MIF-induced lung inflammation. We
have previously shown that MIF itself causes neutrophil
accumulation into the alveolar space [25]. MIF is an intra-
cellular protein that can be released into the extracellular
environment where it acts as a potent inflammatory stim-
ulant. Extracellular MIF can bind to the cell surface mole-
cule CD74.
Therefore we focused on the MIF receptor CD74 in an ani-
mal model. We hypothesized that MIF, in the alveolar
space, results in neutrophil accumulation via activation of
the CD74. Here we used intra-tracheal instillation of MIF,
and studied the contribution of CD74 in MIF-induced
neutrophil accumulation in a mouse model.
The present study demonstrated that MIF instillation
increased the concentration of MIP-2 and KC as well as
the number of neutrophils in the alveolar space. This
study shows that CD74 expressed on the cell surface of
alveolar macrophages, contributes to the MIF-induced
neutrophil accumulation into the alveolar space.
Methods
Mouse model
All experiments were approved by the Institutional Ani-
mal Care and Use Committee at The Feinstein Institute for
Medical Research at North Shore-Long Island Jewish
Health System. C57Bl/6 male mice (8–12 weeks old) were
anesthetized with isoflurane and the trachea was surgi-
cally exposed. Recombinant murine MIF (r-MIF; 1.0 μg in
50 μl normal saline) or 50 μl normal saline alone (con-
trol) was instilled directly into the lungs via the trachea
using a 29 gauge needle. Groups of mice (n = 6/group)
were euthanized at 3, 6 and 20 hours post instillation,
blood was collected by cardiac puncture. The blood sam-
ples were centrifuged (2000 × g, 10 min), and the plasma
was stored at -80°C for further examination. Postmortem
bronchoalveolar lavage (BAL) was performed by instilling
and withdrawing sterile physiological saline (1 ml)
through a tracheal cannula using a 20 gauge Surflo i.v.
catheter (Terumo, Elkton, MD). This procedure was
repeated three times, and the three BAL fluid samples were
pooled. Lung tissues were then isolated and frozen imme-
diately in liquid nitrogen. The BAL fluid was centrifuged
(300 × g, 5 min), and the supernatant portions were
stored at -80°C for further examination.
Differential cell count in BAL fluid
Immediately after collection of BAL fluids, erythrocytes
were lysed using 0.2% saline and the remaining cells were
resuspended in Hanks' Balanced Salt Solution (Invitro-
gen, Grand Island, NY). Total cell count of each BAL sam-
ple was determined using a Neubauer hemocytometer
(Hausser Scientific, Horsham, PA). Differential cell counts
were performed (200 cells for each experimental condi-
tion) on cytospin slides stained with Protocol HEMA3
solution (Fisher scientific, Fair Lawn, NJ). Total protein
concentration in BAL fluid was measured using Coomas-
sie protein assay kit (Thermo Scientific, Rockford, IL).Respiratory Research 2009, 10:33 http://respiratory-research.com/content/10/1/33
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Reagents and antibodies
r-MIF was prepared from an Escherichia coli expression
system, and treated with polymyxin B as previously
described [26]. The MIF specific inhibitor (S, R)-3-(4-
hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid
methyl ester (ISO-1) was diluted for use with a minimal
amount of dimethyl sulfoxide (DMSO, Fisher Scientific,
Fair Lawn, NJ) as previously described [24,27,28]. Anti-
CD74 antibody (clone; In-1) for western blotting was pur-
chased from BD Bioscience (San Jose, CA), and anti-CD74
goat polyclonal antibody for flow cytometry and immun-
ofluorescence was purchased from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA). Anti-phospho p44/p42 MAPK,
anti-phospho p38 MAPK, anti-p38 MAPK, anti-phospho
JNK, anti-JNK and anti-GAPDH antibodies were pur-
chased from Cell Signaling Technology (Danvers, MA).
Stripping buffer for membrane was purchased from
Thermo Scientific (Rockford, IL). Anti-p44/p42 MAPK
antibody and isotype control goat IgG were purchased
from Santa Cruz Biotechnology Inc. MAPK specific inhib-
itor PD98059 and p38 MAPK specific inhibitor SB202190
were purchased from Calbiochem (San Diego, CA).
Cell culture
Murine macrophages (RAW264.7) and murine alveolar
type II epithelial cells (MLE-12) were purchased from
American Type Culture Collection (Manassas, VA).
RAW264.7 cells were cultured in DMEM supplemented
with 10% heat-inactivated fetal calf serum (FCS), L-
glutamine, penicillin and streptomycin (Invitrogen,
Grand Island, NY) at 37°C in a 5% CO2 humidified incu-
bator. MLE-12 cells were cultured in DMEM/F12 media
supplemented with 2% FCS, 15 mM HEPES, L-glutamine,
penicillin and streptomycin [29,30]. In experiments of
anti-CD74 antibody and ISO-1 treatment in vitro,
RAW264.7 cells were treated with 10 μg/ml anti-CD74
antibody or 10 μg/ml control goat IgG at 37°C for 30 min.
After 30 min pre-treatment, cells were stimulated with
100 ng/ml MIF at 37°C for 10 min. In addition, 100 mM
ISO-1 in PBS or 5% DMSO in PBS and 100 ng/ml MIF
were mixed in microtubes at 37°C for 30 min, then cells
were stimulated with the mixture at 37°C for 10 min.
Cells were lysed and subjected to SDS-PAGE, then immu-
noprobed by anti-phospho and total p44/p42 MAPK anti-
body.
Western blot analysis
A total of 1.0 × 106 RAW264.7 cells/sample were stimu-
lated with various concentrations of r-MIF in 1% FCS con-
taining media. After washing (×2) with ice cold PBS
buffer, cells were lysed in lysis buffer containing 150 mM
NaCl, 50 mM Tris-HCl (pH 7.4), 2 mM EDTA (pH 8.0),
1% octylphenol polyethyleneglycol (NP-40), 0.5% deox-
ycholic acid, 0.1% SDS, and 1 mM PMSF. Lysates were
separated from debris by centrifugation (7800 × g) for 15
min, and lysates were boiled for 5 min in Laemmli sample
buffer (Bio-Rad Laboratories, Hercules, CA) under reduc-
ing conditions. Tissues were thawed and homogenized in
lysis buffer at 4°C, and incubated on ice for 30 min, then
centrifuged (7800 × g) for 15 min at 4°C. The superna-
tants were analyzed for protein content, and were boiled
for 5 min in Laemmli sample buffer (Bio-Rad Laborato-
ries). Proteins (total protein content was 15 μg/lane) were
separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), and transferred to a polyvi-
nylidine difluoride membrane (Millipore, Billerica, MA).
Prestained molecular weight standards (Crystalgen Inc.,
Plainview, NY) were run with each gel to determine the
approximate molecular weight of detected bands. Then
membranes were incubated with the specific primary anti-
bodies and horse radish peroxidase (HRP) conjugated sec-
ondary antibodies. After washing with tris-buffered saline
contained 0.1% tween-20 (TBS-T), membranes were incu-
bated with Chemiluminescence Luminol Reagent (Amer-
sham Biosciences, Pittsburgh, PA) and exposed to
photographic film (Fujifilm Corp, Tokyo, Japan). Protein
bands were quantified by densitometric analysis using a
Gel Doc 2000 Chemi Doc scanner (Bio-Rad Laboratories)
and Quantity One 4.4.0 software.
Cell staining and flow cytometry
Single-cell suspensions were incubated at 4°C for 2 hours
with anti-CD74 antibody or control IgG diluted in stain-
ing buffer (PBS containing 2% FCS). Cells were washed
with staining buffer, and then incubated at 4°C for 30
min with FITC-conjugated secondary antibody. Flow
cytometry analysis was performed on FACSCalibur (BD
Biosciences, San Jose, CA) and data were analyzed using
CellQuest software.
Cytokine analysis
Cytokine concentrations were evaluated using commer-
cially available enzyme-linked immunosorbent assay
(ELISA) kits for keratinocyte-derived chemokine (KC;
CXCL1) and macrophage inflammatory protein 2 (MIP-2;
CXCL2) from R&D Systems. (Minneapolis, MN).
Histological study
To obtain lungs for routine histology, the trachea was can-
nulated and the lungs were gently fixed at inflation with
4% paraformaldehyde solution. The fixed lungs were sec-
tioned (5 μm), and the sections stained with hemotoxylin
and eosin (Sigma-Aldrich, St. Louis, MO). For identifica-
tion of neutrophils, the sections were stained with naph-
thol AS-D chloroacetate esterase (Sigma-Aldrich, St. Louis,
MO).
Immunofluorescence study
Cells from BAL fluid were prepared using cytospin centrif-
ugation. The slides were fixed in 4% paraformaldehyde inRespiratory Research 2009, 10:33 http://respiratory-research.com/content/10/1/33
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PBS, pH 7.4 for 10 min at room temperature (RT) and per-
meabilized with 0.01% Triton X-100 in PBS for 5 min at
RT. After washing with PBS, each slide was blocked with
10% rabbit serum in PBS for 1 hour at RT. Slides were then
incubated with anti-CD74 polyclonal antibody or control
IgG diluted in blocking solution for 18 hours at 4°C, and
were incubated with FITC-conjugated secondary antibody
diluted in blocking solution for 1 hour at RT. After wash-
ing with PBS, slides were incubated with 4', 6-diamidino-
2-phenylindole, dihydrochloride (DAPI, AnaSpec Inc. San
Jose, CA) in blocking solution for 30 min at RT. Cover
slips were then placed on the slides with mounting
medium (Vector laboratories, Inc. Burlingame, CA).
Images were obtained using a Zeiss ApoTome fluorescent
microscope and Zeiss Axiovision software (Zeiss LSM,
Thornwood, NY).
Statistical analysis
All values are expressed as mean ± standard deviation
(SD). Multiple groups were compared using analysis of
variance (ANOVA) using the Dunnett's post hoc test.
Results were considered statistically significant at p < 0.05.
Results
MIF induces neutrophil accumulation into the lung
We have previously reported that MIF has the ability to
induce neutrophil accumulation into the alveolar space of
mice [25]. To examine the kinetics of MIF-induced leuko-
cytosis, C57Bl/6 mice were instilled intratracheally with r-
MIF and the influx of neutrophils was examined over
time. The number of neutrophils in BAL fluid at 3, 6 or 20
hours after instillation of MIF significantly increased com-
pared to control animals in which normal saline was
instilled alone (Fig. 1A). The number of neutrophils was
highest at 6 hours post instillation (total number of neu-
trophils, saline; 0.09 ± 0.04 × 104, 3 hours; 2.95 ± 1.13 ×
104, 6 hours; 5.10 ± 1.35 × 104, 20 hours; 4.18 ± 1.31 ×
104). At 6 hours post instillation neutrophil number
increased not only in the BAL fluid (Fig. 1B, i and 1B, iv)
but also in the alveolar tissue (Fig. 1B, ii, iii, v, vi). BAL flu-
ids were assessed for total protein content, and the neu-
trophil chemoattractants MIP-2 and KC. Total protein
concentration in BAL fluids significantly increased at 6
hours after MIF instillation (Fig. 2A, saline; 71.9 ± 21.1
μg/ml, 3 hours; 130.4 ± 58.5 μg/ml, 6 hours; 158.7 ± 53.6
μg/ml, 20 hours; 127.9 ± 44.5 μg/ml). Furthermore, MIP-
2 and KC in BAL fluids increased at 3, 6 hours after instil-
lation and peaked around 3 hours (Fig. 2B, the concentra-
tion of MIP-2 at 3 hours; 422.7 ± 125.7 pg/ml, Fig. 2C, the
concentration of KC at 3 hours; 1859.4 ± 684.1 pg/ml).
However, MIP-2 and KC concentrations in plasma from
these mice did not significantly change following MIF
instillation (data not shown).
Macrophages express MIF receptor component CD74
MIF intratracheal instillation markedly induced neu-
trophil accumulation in the lung. To determine the
involvement of CD74 in the MIF-induced responses, we
examined CD74 expression in several cell types. We used
RAW264.7 cells and the MLE-12 cells as models of alveo-
lar macrophages and type II alveolar epithelial cells
respectively, and assayed for the presence of CD74 in
RAW264.7, MLE-12 and lung tissues. Two isoforms of
CD74 (p41 and p31) were observed. There was higher
expression of CD74 protein in RAW264.7 and lung tissues
than in MLE-12 cells (Fig. 3A). To confirm CD74 expres-
sion in primary alveolar macrophages in BAL fluid, we
used immunofluorescence microscopy. We found that
CD74 protein is also expressed in alveolar macrophages
(Fig. 3B). More than 95% of the cells in BAL fluid were rec-
ognized as macrophages using stained cytospin slides in
this experiment. Furthermore, cell surface expression of
CD74 was evident in non-permeabilized RAW264.7 and
alveolar macrophages but not in MLE-12 (Fig. 3C).
MIF activates p44/p42 MAPK pathway and stimulates 
MIP-2 release from macrophages
Following MIF stimulation, the p44/p42 MAPK signaling
pathway was activated in both a time and dose dependent
manner in RAW264.7 macrophage cells (Fig. 4A, 4B).
However, there was no significant activation of p38 MAPK
or JNK signaling pathways (data not shown). To investi-
gate whether MIF stimulation induces the release of neu-
trophil chemokines, we measured MIP-2 and KC in cell
culture supernatants. There was a significant accumula-
tion of MIP-2 (Fig. 4C, MIP-2 at 100 ng/ml stimulation;
1243.1 ± 35.3 pg/ml) but not KC (data not shown) in the
culture media following stimulation with MIF. To confirm
that activation of MIP-2 is downstream of p44/p42 MAPK
following MIF stimulation, specific MAP kinase inhibitors
were used. The p44/p42 MAPK specific inhibitor
PD98059 attenuated the MIF-induced MIP-2 accumula-
tion (Fig. 5, MIF; 1219.7 ± 48.1 pg/ml, MIF + PD; 752.2 ±
42.6 pg/ml, p < 0.05). However, the p38 MAPK inhibitor
SB202190 had no effect on the MIP-2 accumulation (Fig.
5, MIF + SB; 1307.6 ± 68.8 pg/ml). This suggests that MIF-
induced MIP-2 accumulation depends, at least in part, on
p44/p42 MAPK signaling pathway.
Anti-CD74 antibody inhibits MIF-induced p44/p42 MAPK 
phosphorylation and MIP-2 accumulation in macrophages
MIF signaling occurs following MIF binding to CD74. To
examine whether neutralization of CD74 can inhibit the
MIF-induced cell signaling, we used a CD74 antibody,
and the specific MIF inhibitor, ISO-1 [24,27,28]. We
found that both CD74 antibody and ISO-1 treatment sig-
nificantly inhibited MIF-induced phosphorylation of
p44/p42 MAPK (Fig. 6A, relative ratio, MIF + control IgG;
2.98 ± 0.33, MIF + CD74 Ab; 2.07 ± 0.19, p < 0.05, MIF +Respiratory Research 2009, 10:33 http://respiratory-research.com/content/10/1/33
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MIF induces neutrophil accumulation into the alveolar space Figure 1
MIF induces neutrophil accumulation into the alveolar space. Mice were euthanized at 3, 6 or 20 hours post instilla-
tion of 1.0 μg MIF or 3 hours (saline controls). Lungs were lavaged three times with normal saline. A. The number of neu-
trophil in the bronchoalveolar lavage (BAL) fluid was counted by hemocytometer. Bars indicate mean ± SD (n = 6/group). *P < 
0.05 compared with normal saline control. B. (i), (iv) show the cell population in BAL fluid with HEMA3 stain. (i)-(iii) shows 
representative samples from a control mouse, and (iv)-(vi) shows samples from 6 hours after MIF instilled mice. Lung tissue 
stained with H-E stain in (ii), (v) and naphthol AS-D chloroacetate esterase stain (neutrophil granules were stained with bright 
red color, point with arrows) in (iii), (vi).
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Alveolar protein and chemokine response following intratracheal instillation of MIF Figure 2
Alveolar protein and chemokine response following intratracheal instillation of MIF. Mice were euthanized at 3, 6 
or 20 hours post instillation of MIF, and the lungs were lavaged with normal saline. A. Total protein concentration in BAL fluid 
after 3, 6, 20 hours. B. MIP-2 concentration in BAL fluid after 3, 6, 20 hours measured by ELISA. C. KC concentration in BAL 
fluid measured by ELISA. Bars indicate mean ± SD (n = 6/group). *P < 0.05 compared with normal saline control.
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Figure 3 (see legend on next page)
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DMSO; 2.96 ± 0.38, MIF + ISO-1; 1.79 ± 0.27, p < 0.05).
Furthermore, both ISO-1 and CD74 antibody treatment
inhibited MIF-induced MIP-2 accumulation in culture
media (Fig. 6B, MIF + control IgG; 1348.7 ± 107.3 pg/ml,
MIF + CD74 Ab; 873.0 ± 47.1 pg/ml, p < 0.05, MIF +
DMSO; 1372.2 ± 34.6 pg/ml, MIF + ISO-1; 635.7 ± 42.5
pg/ml, p < 0.05). These data suggest that anti-CD74 anti-
body has a similar effect as ISO-1 treatment in inhibiting
MIF-induced cell activation.
Anti-CD74 antibody inhibits MIF-induced neutrophil 
accumulation into the alveolar space
In the next series of experiments, MIF was intratracheally
instilled in the presence of anti-CD74 antibody or ISO-1,
an MIF inhibitor that blocks binding to CD74. Mixtures of
either 1.0 μg MIF and 10 μg anti-CD74 antibody or 1.0 μg
MIF and 0.5 μg ISO-1 were instilled via the trachea to
ensure identical distribution of both agonist and inhibi-
tor. Anti-CD74 antibody and ISO-1 significantly inhibited
MIF-induced neutrophil accumulation into the lung (Fig.
7A, total number of neutrophils, MIF + control IgG; 3.33
± 0.92 × 104, MIF + CD74 Ab; 1.90 ± 0.61 × 104, p < 0.05,
MIF + DMSO; 3.65 ± 0.82 × 104, MIF + ISO-1; 1.53 ± 0.69
× 104, p < 0.05). To assess the effect of anti-CD74 anti-
body treatment on chemokine accumulation, MIP-2 and
KC concentrations were measured in the BAL fluids. Anti-
CD74 antibody and ISO-1 treatment significantly inhib-
ited the MIF-induced MIP-2 (Fig. 7B, MIF + control IgG;
477.1 ± 136.7 pg/ml, MIF + CD74 Ab; 242.2 ± 102.2 pg/
ml, p < 0.05, MIF + DMSO; 405.3 ± 130.5 pg/ml, MIF +
ISO-1; 210.6 ± 60.6 pg/ml, p < 0.05) and KC accumula-
tion in BAL fluids (Fig. 7C, MIF + control IgG; 1796.2 ±
436.1 pg/ml, MIF + CD74 Ab; 1138.2 ± 310.3 pg/ml, p <
0.05, MIF + DMSO; 1659.8 ± 444.5 pg/ml, MIF + ISO-1;
763.4 ± 271.4 pg/ml, p < 0.05). Taken together, anti-
CD74 antibody and ISO-1 both had an inhibitory effect
on MIF-induced MIP-2, KC accumulation and resultant
neutrophil accumulation into the alveolar space. These
data suggest that CD74 has a pivotal role in MIF-induced
neutrophil accumulation into the alveolar space.
Discussion
MIF is expressed in multiple immune and nonimmune
cell types and is released in response to infection and
other stresses [1]. MIF exists as a homotrimer, each mon-
omer being approximately 12.5 kDa. MIF has enzymatic
activities, and is a potent regulator of innate and adaptive
immune responses [1]. MIF has immunoregulatory func-
tions in sepsis [2], ARDS[3], bronchial asthma [31], rheu-
matoid arthritis [5] and tumorgenesis [32].
Neutrophils play an important role in the inflammatory
response, and can be associated with severe lung injury in
patients with the acute respiratory distress syndrome
(ARDS) [11]. Previous studies suggest that MIF partici-
pates in neutrophil accumulation into the lung after intra-
peritoneal LPS injection [15]. In the LPS intratracheal
instillation model, neutralization of MIF attenuated capil-
lary leak and the levels of TNF-α and IL-6 in BAL fluid
[14]. The elimination of neutrophils, using anti-neu-
trophil antibody, markedly decreases the severity of ani-
mal acute lung injury in animal models [13]. Neutrophil
recruitment from blood into tissue at sites of inflamma-
tion usually occurs in post-capillary venules and requires
capture, rolling and adhesion on endothelial cells in acute
lung injury [12]. A multitude of molecules including
selectin, integrin, and immunoglobulin adhesion mole-
cules, cytokines and chemokines participate in this
sequential process in a variety of vascular beds [33,34].
The CXC chemokine interleukin-8 (IL-8) has been impli-
cated in mediating the influx of neutrophils into the lung
in ARDS patients [35,36], particularly sepsis-associated
ARDS [37]. The murine equivalents of IL-8, MIP-2 and
KC, have been reported to be the two most crucial chem-
okines for neutrophil recruitment [38]. Neutralization of
MIP-2 significantly decreases neutrophil recruitment into
the lung [39]. Both MIP-2 and KC bind to CXCR2 recep-
tors, and blockade of CXCR2 attenuates neutrophil influx
into the lung [40-43].
In the present study, we investigated the contribution of
macrophage CD74 in MIF-induced neutrophil accumula-
tion into the alveolar space. We showed previously that
CD74 expresses on the cell surface of alveolar macrophages Figure 3 (see previous page)
CD74 expresses on the cell surface of alveolar macrophages. A. RAW264.7, MLE-12 and lung tissues from two non-
treated mice were homogenized in lysis buffer and prepared for western blot analysis for CD74. The blots were then stripped 
and re-probed for GAPDH antibody as a loading control (total protein content was 15 μg/lane). Data represents three inde-
pendent experiments. B. BAL cells from mice were stained with anti-CD74 antibody or control IgG and subsequent FITC-con-
jugated secondary antibody after fixation and permeabilization. (i), (ii) show the control IgG and (iii), (iv) show anti-CD74 
antibody. (i), (iii) show differential interference contrast (DIC) and (ii), (iv) show fluorescent image. Green color represents 
CD74 or control IgG (FITC) and blue color represents nuclear (DAPI). Scale bar represents 20 μm. Data represents four inde-
pendent experiments. C. Flow cytometry of non-permeabilized RAW264.7, MLE-12 and alveolar macrophages assessing sur-
face expression of CD74. Shaded histograms show CD74 staining, and opened histograms show the control IgG staining. Data 
shown is representative of three independent experiments.Respiratory Research 2009, 10:33 http://respiratory-research.com/content/10/1/33
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MIF activates p44/p42 MAPK pathway and stimulates MIP-2 release from macrophages Figure 4
MIF activates p44/p42 MAPK pathway and stimulates MIP-2 release from macrophages. A. RAW264.7 cells were 
stimulated with 100 ng/ml MIF for 5, 10, 15, 30 or 60 min. After stimulation the cells were lysed and boiled for SDS-PAGE anal-
ysis. Transferred proteins were detected by anti-phospho and total p44/p42 MAPK antibodies. Data represents four independ-
ent experiments. B. RAW264.7 cells were stimulated with 5, 20, 100 ng/ml MIF for 10 min. Proteins were detected by anti-
phospho and total p44/p42 MAPK antibodies. Data represents three independent experiments. C. RAW264.7 cells were stim-
ulated with different concentrations of MIF (20, 50, 100 ng/ml) or control media for 18 hours at 37°C. After 18 hours superna-
tants were collected and MIP-2 concentrations were measured by ELISA. Bars indicate mean ± SD (n = 3/group). Data is 
representative of four independent experiments. *P < 0.05 compared with control media.
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MIF has the ability to induce neutrophil accumulation
[25]. These data suggest that MIF stimulates some types of
cells in the alveolar space, to release MIP-2 and KC, which
result in neutrophil accumulation in the alveolar space.
Although the number of neutrophils in the alveolar space
was less than in bacteria or bacterial component induced
lung injury models, the current study showed that MIF
administration can result in neutrophil accumulation
(Fig. 1). While MIF has potent inflammatory and immu-
noregulatory properties, the mechanisms of cellular bind-
ing and activation remain to be fully elucidated. The
extracellular domain of CD74 has been shown to bind
MIF with high affinity and act as a surface membrane
receptor [17]. Theoretically, MIF signaling is initiated after
MIF binding to cell surface CD74. Recently, others have
reported that expression of CD74 in mouse lung sections
was predominantly localized to alveolar macrophage and
type II alveolar epithelial cells [44]. Therefore we exam-
ined CD74 protein level and CD74 cell surface expression
in macrophages and epithelial cells. Interestingly, we
found that CD74 is expressed on the alveolar macrophage
cell surface, suggesting that macrophages could respond
to extracellular MIF (Fig. 3). In addition, we have shown
that macrophages can release MIP-2 following MIF stimu-
lation (Fig. 4C), and MIF-induced MIP-2 accumulation
depends, at least in part, on p44/p42 MAPK signaling
pathways as indicated in the specific inhibitor study in
macrophages (Fig. 5).
The neutralization of MIF is a promising approach to
develop new anti-inflammatory agents and treatments for
diseases that involve increased MIF production or release
[45,46]. In fact, an administration of neutralizing anti-
MIF antibodies has proven therapeutically effective in ani-
mal models of sepsis [9] and in LPS-induced lung injury
models [15,16]. X-ray crystallography studies show that
ISO-1, an MIF-specific inhibitor, binds to the inflamma-
tory active site of MIF in [27,28]. Treatment with ISO-1
has been reported to be effective in endotoxemia [27],
polymicrobial sepsis [24] and autoimmune diabetes
models [47]. Leng and colleagues have shown that anti-
CD74 antibody can block MIF-induced cell proliferation
in B cells and fibroblast cells [17]. Other recent studies
have demonstrated that anti-CD74 antibody blocks MIF-
CD74 binding in the cell surface of gastric epithelial cells
[21], and anti-CD74 antibody attenuated proliferation of
prostate cancer cells [22]. Moreover, a humanized anti-
CD74 monoclonal antibody (hLL1) treatment has been
reported to have therapeutic potential for B-cell malignan-
cies [48]. In our study, we have shown that anti-CD74
antibody significantly inhibited the MIF-induced p44/
p42 MAPK phosphorylation and MIP-2 accumulation
(Fig. 6), suggesting that the MIF-induced MIP-2 accumu-
lation depends, at least in part, on cell surface CD74 of
macrophages.
We used anti-CD74 antibody in our mouse model, and
have shown that anti-CD74 antibody significantly inhib-
ited the MIF-induced neutrophil accumulation into the
alveolar space as well as accumulation of MIP-2, KC (Fig.
7). The results revealed that anti-CD74 antibody has the
ability to inhibit MIF-induced neutrophil accumulation in
vivo. In this study, we have instilled mixtures of either MIF
and ISO-1 or MIF and anti-CD74 antibody to ensure that
MIF and inhibitor are delivered to an identical segment of
the lung. This is important, because we believe that the
native MIF binds to the receptor (CD74) to effect the
inflammatory response and that the inhibitor or antibody
blocks the MIF-receptor interaction. Future studies will
address the question of whether the inflammatory
response induced by MIF-CD74 interactions can be atten-
uated by intravenous administration of ISO-1 or anti-
CD74 antibody, and the effective time course of adminis-
tration. We believe a combination of CD74 antibody and
other anti-inflammatory agents might be beneficial for
treatment of neutrophilic lung inflammation.
Anti-CD74 antibody treatment reduced the number of
neutrophils compared to control at 43%. This suggests
that anti-CD74 antibody had a partial inhibitory effect in
MIF-induced neutrophil accumulation. The data raises the
possibility that MIF could activate via other signaling
pathways, not CD74 alone. Indeed, an MIF endocytotic
pathway has been proposed, in which MIF is taken up by
MIF-induced MIP-2 accumulation depends on p44/p42 MAPK  pathway Figure 5
MIF-induced MIP-2 accumulation depends on p44/
p42 MAPK pathway. RAW264.7 cell were incubated with 
MAP kinase kinase (MEK) specific inhibitor (PD98059, 30 
mM) or p38 MAP kinase specific inhibitor (SB202190, 30 
mM) or DMSO for 30 min before stimulation with 100 ng/ml 
MIF. After 18 hours stimulation, supernatants were collected 
and MIP-2 concentrations in supernatants were measured by 
ELISA. Bars indicate mean ± SD (n = 3/group). Data is repre-
sentative of three independent experiments. *P < 0.05 com-
pared with DMSO + MIF.
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Anti-CD74 antibody treatment inhibits MIF-induced p44/p42 MAPK phosphorylation and MIP-2 accumulation in macrophages Figure 6
Anti-CD74 antibody treatment inhibits MIF-induced p44/p42 MAPK phosphorylation and MIP-2 accumulation 
in macrophages. A. RAW264.7 cells were treated with 10 μg/ml anti-CD74 antibody or control IgG, or 100 mM ISO-1 or 
DMSO control for 10 min. Cells were lysed and subjected to SDS-PAGE, immunoprobed by anti-phospho and total p44/p42 
MAPK antibody. Bar graphs show the density ratio of phospho- vs. total-p44/p42 MAPK bands. Bar graphs represent the mean 
± SD of three independent experiments. B. RAW264.7 cells were treated with 10 μg/ml anti-CD74 antibody or control IgG, or 
100 mM ISO-1 or DMSO control for 18 hours. After 18 hours supernatant were collected and MIP-2 concentration were 
measured by ELISA. Bars indicate mean ± SD (n = 3/group). Data represents four independent experiments. *P < 0.05 com-
pared with control IgG + MIF or DMSO + MIF stimulation.
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Anti-CD74 antibody treatment inhibits MIF-induced neutrophil accumulation into the alveolar space Figure 7
Anti-CD74 antibody treatment inhibits MIF-induced neutrophil accumulation into the alveolar space. A. The 
number of neutrophils in BALF from treated mice. The groups of mice were instilled via the trachea with either 1.0 μg MIF plus 
10 μg anti-CD74 antibody or 1.0 μg MIF plus 10 μg control IgG. The other groups of mice were instilled with either 1.0 μg MIF 
plus 0.5 mg ISO-1 or 1.0 μg MIF plus 5% DMSO. Mice were euthanized 3 hours post instillation, then lungs were lavaged three 
times with normal saline. The number of neutrophils were counted using a hemocytometer. *P < 0.05 compared with control 
IgG + MIF or DMSO + MIF stimulation, B. MIP-2, and C. KC concentration in BAL fluid from 3 hours post instilled mice meas-
ured by ELISA. Bars indicate mean ± SD (n = 6/group). *P < 0.05 compared with control IgG + MIF or DMSO + MIF stimula-
tion.
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the cell and binds to Jun activation domain-binding pro-
tein (Jab1) (COP9 signalosome subunit 5; CNS5). MIF
would thereby inhibit Jab1-enhanced AP-1 transcrip-
tional activity [49]. A recent study has shown that MIF
activates p44/p42 MAPK pathway rapidly and transiently
in a Jab1 dependent manner [50].
Conclusion
This study shows that CD74 is expressed on the cell sur-
face of alveolar macrophages, and potentially contributes
to MIF-induced neutrophil accumulation into the alveolar
space. We have demonstrated that anti-CD74 antibody
inhibits MIF-induced p44/p42 MAPK phosphorylation
and MIP-2 release in macrophages. Furthermore, we have
demonstrated that anti-CD74 antibody treatment inhibits
MIF-induced MIP-2, KC accumulation and neutrophil
accumulation in mouse model. The data suggest that MIF
and its receptor CD74 may be useful targets to reduce neu-
trophilic lung inflammation, and acute lung injury.
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